Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.
Smolewski P et al. Eur J Cancer. 2014 Aug 18. pii: S0959-8049(14)00873-9. doi: 10.1016/j.ejca.2014.07.021. [Epub ahead of print].
Cell membrane associated free kappa light chains are found on a subset of tonsil and in vitro-derived plasmablasts.
Hutchinson AT et al. Hum Immunol. 2014 Aug 19. pii: S0198-8859(14)00395-4. doi: 10.1016/j.humimm.2014.08.196. [Epub ahead of print].
Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Kim M et al. Genes Chromosomes Cancer. 2014 Aug 21. doi: 10.1002/gcc.22213. [Epub ahead of print].
FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells.
Braga WM et al. Cancer Immunol Immunother. 2014 Aug 7. [Epub ahead of print].
Game theory in the death galaxy: interaction of cancer and stromal cells in tumour microenvironment.
Wu A et al. Interface Focus. 2014 Aug 6;4(4):20140028. doi: 10.1098/rsfs.2014.0028.
Overview and Perspective of Proteasome Inhibitor-Based Anti-Cancer Therapies: Bortezomib and Second Generation Proteasome Inhibitors Versus Future Generation Inhibitors of Ubiquitin-Proteasome System.
Dou QP et al. Curr Cancer Drug Targets. 2014 Aug 4. [Epub ahead of print].
The evolving tale of IMiDs and cereblon.
Holstein SA. Clin Pharmacol Ther. 2014 Aug 21. doi: 10.1038/clpt.2014.168. [Epub ahead of print].
Stimulation of invariant natural killer T cells by α-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.
Nur H et al. Br J Haematol. 2014 Aug 21. doi: 10.1111/bjh.13092. [Epub ahead of print].
Formation of Amyloid Fibers by Monomeric Light-chain Variable Domains.
Brumshtein B et al. J Biol Chem. 2014 Aug 19. pii: jbc.M114.585638. [Epub ahead of print].
SDF-1α stiffens myeloma bone marrow mesenchymal stromal cells through the activation of RhoA-ROCK-Myosin II.
Choi DS et al. Int J Cancer. 2014 Aug 18. doi: 10.1002/ijc.29145. [Epub ahead of print].
Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells.
Kim SM et al. Cancer Lett. 2014 Aug 14. pii: S0304-3835(14)00430-3. doi: 10.1016/j.canlet.2014.08.002. [Epub ahead of print].
Score test variable screening.
Zhao SD et al. Biometrics. 2014 Aug 14. doi: 10.1111/biom.12209. [Epub ahead of print].
Inhibition of sphingosine kinase 2 down-regulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Kummetha Venkata J et al. Blood. 2014 Aug 13. pii: blood-2014-03-559385. [Epub ahead of print].
Toll-like receptors in the pathogenesis of human B cell malignancies.
Isaza-Correa JM et al. J Hematol Oncol. 2014 Aug 12;7(1):57. [Epub ahead of print].
Overcoming bortezomib resistance in multiple myeloma.
Murray MY et al. Biochem Soc Trans. 2014 Aug 1;42(4):804-8. doi: 10.1042/BST20140126.
Cellular immunotherapy in multiple myeloma: Lessons from preclinical models.
Binsfeld M et al. Biochim Biophys Acta. 2014 Aug 7. pii: S0304-419X(14)00067-5. doi: 10.1016/j.bbcan.2014.08.001. [Epub ahead of print].
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Chamberlain PP et al. Nat Struct Mol Biol. 2014 Aug 10. doi: 10.1038/nsmb.2874. [Epub ahead of print].
IκB kinaseβ (IKBKB) Mutations in Lymphomas that constitutively activate Canonical nuclear factor κB (NFκB) signaling.
Kai X et al. J Biol Chem. 2014 Aug 8. pii: jbc.M114.598763. [Epub ahead of print].
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
Ocio EM et al. Leukemia. 2014 Aug 8. doi: 10.1038/leu.2014.238. [Epub ahead of print].
Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma.
Waizenegger JS et al. Leukemia. 2014 Aug 8. doi: 10.1038/leu.2014.236. [Epub ahead of print].
Molecular pathways: translational potential of deubiquitinases as drug targets.
D’Arcy P et al. Clin Cancer Res. 2014 Aug 1;20(15):3908-14. doi: 10.1158/1078-0432.CCR-14-0568.
Role of Bruton’s tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.
Bam R et al. Blood Cancer J. 2014 Aug 1;4:e234. doi: 10.1038/bcj.2014.54.
The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma.
Kassen D et al. Br J Haematol. 2014 Jul 31. doi: 10.1111/bjh.13020. [Epub ahead of print].
Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma.
Heuck CJ et al. Leukemia. 2014 Jul 31. doi: 10.1038/leu.2014.232. [Epub ahead of print].
Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.
Luetkens T et al. Cancer Immunol Immunother. 2014 Jul 31. [Epub ahead of print].
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.
Campa D et al. Int J Cancer. 2014 Jul 28. doi: 10.1002/ijc.29101. [Epub ahead of print].
The relationship between the pro-oxidant and antioxidant system status of patients with multiple myeloma and the disease stage.
Smirnova OV et al. Bull Exp Biol Med. 2014 Jul;157(3):375-9. doi: 10.1007/s10517-014-2570-5. Epub 2014 Jul 29.
Relevance of the thyroid hormones-αvβ3 pathway in primary myeloma bone marrow cells and to bortezomib action.
Cohen K et al. Leuk Lymphoma. 2014 Aug 20:1-8. [Epub ahead of print].
Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation.
Arendt BK et al. Oncotarget. 2014 Jul 30;5(14):5686-99.